Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 9;251:196–201.e4. doi: 10.1016/j.jpeds.2022.07.056

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Elsevier Inc. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Incidence of total SARS-CoV-2 infection and SARS-CoV-2 infection after vaccination at Lurie Children's during the A, pre-Omicron study period (May 15, 2021, to December 11, 2021, prior to the substantial surge in SARS-CoV-2 infection activity) and B, the complete study period (May 15, 2021, to January 1, 2022). The solid line represents the total incidence of pediatric SARS-CoV-2 infection, and the dashed line represents the total incidence of SARS-CoV-2 infection after vaccination. In B, arrows indicate date of Food and Drug Administration Emergency Use Authorization of Pfizer-BioNTech SARS-CoV-2 mRNA vaccine in children and young adults aged 0-20 years. Not shown is the initial authorization of SARS-CoV-2 vaccine in adolescents aged 16+ years on December 11, 2020.